Atty Dkt. No.: BERK-017CIP

USSN: 10/547,999

In the Claims:

Claims 1-13. (Canceled)

14. (**Currently Amended**) A method of eliciting or boosting a cellular immune response to an antigen in a subject, said method comprising:

administering to said subject an effective amount of Listeria

administering to said subject an effective amount of Listeria cells **that express said antigen**, wherein said cells are transformed with an integration vector capable of site-specific Listeria genome integration, **wherein said integration vector comprises**

a listeriophage attachment site.

15. (Original) The method according to Claim 14, wherein said Listeria cells are attenuated.

16. (Withdrawn) A vaccine comprising a strain of Listeria cells according to Claim

13, wherein said Listeria cells express a heterologous antigen.

17. (Withdrawn) The vaccine according to Claim 16, wherein said Listeria cells are

attenuated.

18. (Withdrawn) A recombinant culture of Listeria cells according to Claim 13.

19. (Withdrawn) The recombinant culture according to Claim 18, wherein said

Listeria cells are attenuated.

20. (Withdrawn) A kit for use in preparing a vector according to Claim 7, said kit

comprising:

a vector according to Claim 1; and

Atty Dkt. No.: BERK-017CIP

USSN: 10/547,999

at least one nuclease that cuts said vector at said multiple cloning site.

21. (Withdrawn) The kit according to Claim 20, wherein said kit further comprises a host cell.

22. (Withdrawn) A kit for use in preparing a cell according to Claim 13, said kit comprising:

a vector according to Claim 1;

at least one nuclease that cuts said vector at said multiple cloning site; and

a Listeria cell.

24. (Withdrawn) A system for preparing a vaccine according to Claim 16, said system comprising:

a vector according to Claim 1;

at least one nuclease that cuts said vector at said multiple cloning site;

a coding sequence for said heterologous antigen;

and

Listeria cells.

- 25. (Previously presented) The method according to Claim 14, wherein said integration vector is a plasmid.
- 26. (**Currently Amended**) The method according to Claim 25, wherein said **integration vector plasmid** comprises a bacteriophage integrase gene and **a bacteriophage** attachment site.
- 27. (Canceled)
- 28. (**Currently Amended**) The **[[i]]**method according to Claim 26, wherein said attachment site provides for integration at an integration site selected from the group

Atty Dkt. No.: BERK-017CIP

USSN: 10/547,999

consisting of: the comK integration site and the tRNA^{Arg} integration site.

- 29. (Previously presented) The method according to Claim 14, wherein said integration vector further includes a multiple cloning site.
- 30. (Previously presented) The method according to Claim 29, wherein said integration vector further includes a coding sequence.
- 31. (Previously presented) The method according to Claim 30, wherein said coding sequence encodes a polypeptide.
- 32. (**Currently Amended**) The method according to Claim 31, wherein said polypeptide is **[[an]]** said antigen.
- 33. (Previously Presented) The method according to Claim 14, wherein said integration vector is pPL1.
- 34. (Previously presented) The method according to Claim 14, wherein said integration vector is pPL2.